These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32655548)

  • 1. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity.
    Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK
    Front Immunol; 2020; 11():1055. PubMed ID: 32655548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine.
    Wang R; Gao N; Li Y; Fan D; Zhen Z; Feng K; Chen H; An J
    Front Cell Infect Microbiol; 2019; 9():147. PubMed ID: 31139577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis.
    Gan ES; Ting DH; Chan KR
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):111-119. PubMed ID: 27796143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
    Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
    J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for a dengue virus vaccine.
    Whitehead SS; Blaney JE; Durbin AP; Murphy BR
    Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-dengue Vaccines: From Development to Clinical Trials.
    Pinheiro-Michelsen JR; Souza RDSO; Santana IVR; da Silva PS; Mendez EC; Luiz WB; Amorim JH
    Front Immunol; 2020; 11():1252. PubMed ID: 32655561
    [No Abstract]   [Full Text] [Related]  

  • 12. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
    Wichmann O; Vannice K; Asturias EJ; de Albuquerque Luna EJ; Longini I; Lopez AL; Smith PG; Tissera H; Yoon IK; Hombach J
    Vaccine; 2017 Oct; 35(42):5535-5542. PubMed ID: 28893477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.
    Roth C; Delgado FG; Simon-Lorière E; Sakuntabhai A
    Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29473899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Bull Math Biol; 2020 Jan; 82(1):12. PubMed ID: 31933012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue fever: theories of immunopathogenesis and challenges for vaccination.
    Remy MM
    Inflamm Allergy Drug Targets; 2014; 13(4):262-74. PubMed ID: 25163973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?
    Wen J; Shresta S
    Curr Opin Immunol; 2019 Aug; 59():1-8. PubMed ID: 30884384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development.
    Chokephaibulkit K; Chien YW; AbuBakar S; Pattanapanyasat K; Perng GC
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33167518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.